Continuous vs. Intermittent Infusion Vancomycin

Description

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.

Conditions

Vancomycin

Talk to us

Study Overview

On this page

Study Details

Study overview

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.

A Randomized Clinical Trial of Continuous vs. Intermittent Infusion Vancomycin: Effects on Measured GFR and Kidney Injury Biomarkers

Continuous vs. Intermittent Infusion Vancomycin

Condition
Vancomycin
Intervention / Treatment

-

Contacts and Locations

Lexington

University of Kentucky, Lexington, Kentucky, United States, 40506

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 18 years of age
  • * Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care)
  • * Prescribed ≥ 2 doses of vancomycin per treating physician
  • * Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent.
  • * Chronic kidney disease (documented or prior to admission estimated GFR (eGFR) \<60 ml/min/1.73m2 using non-race-based creatinine GFR equation)
  • * End stage kidney disease
  • * Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase ≥ 0.3 mg/dl or 1.5-1.9 times baseline; urine output \< 0.5 ml/kg/hr for 6-12 hours)
  • * Greater than 2 doses of vancomycin within the last 72 hours
  • * Allergy to iohexol
  • * Uroepithelial tumors
  • * Pregnancy
  • * Prisoner

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Aaron Cook,

Aaron M Cook, PharmD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2024-12-31